Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $16.98

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares gapped down prior to trading on Thursday . The stock had previously closed at $16.98, but opened at $15.80. Tyra Biosciences shares last traded at $15.80, with a volume of 1,351 shares.

Analyst Upgrades and Downgrades

TYRA has been the subject of several recent research reports. Oppenheimer reissued an “outperform” rating and issued a $28.00 price objective (up previously from $25.00) on shares of Tyra Biosciences in a report on Monday, May 13th. Wedbush restated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, May 10th. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Tyra Biosciences in a research note on Wednesday, June 5th.

Tyra Biosciences Trading Up 0.2 %

The stock has a 50-day moving average price of $17.54 and a 200-day moving average price of $16.48.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. On average, sell-side analysts forecast that Tyra Biosciences, Inc. will post -1.71 earnings per share for the current year.

Insider Activity at Tyra Biosciences

In related news, COO Daniel Bensen sold 3,502 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the transaction, the chief operating officer now directly owns 427,981 shares of the company’s stock, valued at approximately $8,559,620. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 15.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tyra Biosciences

A number of large investors have recently modified their holdings of the company. RA Capital Management L.P. raised its holdings in shares of Tyra Biosciences by 43.9% during the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock valued at $170,832,000 after buying an additional 3,180,155 shares in the last quarter. Kynam Capital Management LP increased its stake in Tyra Biosciences by 51.4% in the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after purchasing an additional 175,000 shares during the period. BVF Inc. IL increased its stake in Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares during the period. Vanguard Group Inc. increased its stake in Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after purchasing an additional 140,833 shares during the period. Finally, Oppenheimer & Co. Inc. purchased a new position in Tyra Biosciences in the 1st quarter worth approximately $977,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.